Epizyme - EPZM Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EPZM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EPZM, but not buy additional shares or sell existing shares.
View EPZM analyst ratings or view top-rated stocks.

4 analysts have issued 12-month price targets for Epizyme's stock. Their EPZM share price forecasts range from $1.50 to $6.00. On average, they anticipate the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 104.1% from the stock's current price.
View analysts price targets for EPZM or view top-rated stocks among Wall Street analysts.

Epizyme, Inc. (NASDAQ:EPZM) issued its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.16. The biopharmaceutical company had revenue of $5.20 million for the quarter, compared to analysts' expectations of $8.65 million. Epizyme had a negative trailing twelve-month return on equity of 2,459.33% and a negative net margin of 391.90%. Epizyme's revenue for the quarter was up 45.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.55) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Gilead Sciences (GILD), Nektar Therapeutics (NKTR), Pfizer (PFE), Micron Technology (MU), Novavax (NVAX), CRISPR Therapeutics (CRSP), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD) and Dynavax Technologies (DVAX).

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Epizyme's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Citadel Advisors LLC (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Carl Goldfischer, David M Mott, Jeffery Kutok, Joseph Beaulieu, Matthew Ros, Pablo G Legorreta, Paolo Tombesi, Robert B Bazemore, Robert B Bazemore and Shefali Agarwal.
View institutional ownership trends.

One share of EPZM stock can currently be purchased for approximately $1.47.

Epizyme (NASDAQ:EPZM) has a market capitalization of $247.44 million and generates $37.43 million in revenue each year. The biopharmaceutical company earns $-251,120,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis.

The company employs 250 workers across the globe.

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.epizyme.com. The biopharmaceutical company can be reached via phone at (617) 229-5872, via email at monique@thrustsc.com, or via fax at 617-349-0707.